GSK advances mRNA influenza vaccine to Phase III

GSK reports that its HA/NA-targeting mRNA flu vaccine generated stronger immune responses than licensed comparators, including in older adults, and is moving into a planned September 2026 Phase III efficacy trial with FDA Fast Track status. Protection against influenza illness, durability, safety, and manufacturing benefits remain unknown.